WO2000068209A3 - 1,5-benzodiazepine derivatives as cck-a receptor agonists - Google Patents

1,5-benzodiazepine derivatives as cck-a receptor agonists Download PDF

Info

Publication number
WO2000068209A3
WO2000068209A3 PCT/EP2000/003982 EP0003982W WO0068209A3 WO 2000068209 A3 WO2000068209 A3 WO 2000068209A3 EP 0003982 W EP0003982 W EP 0003982W WO 0068209 A3 WO0068209 A3 WO 0068209A3
Authority
WO
WIPO (PCT)
Prior art keywords
cck
receptor agonists
benzodiazepine derivatives
benzodiazepine
derivatives
Prior art date
Application number
PCT/EP2000/003982
Other languages
French (fr)
Other versions
WO2000068209A2 (en
Inventor
David Colclough
Anne Hodgson
Jerzy Ryszard Szewczyk
Original Assignee
Glaxo Group Ltd
David Colclough
Anne Hodgson
Jerzy Ryszard Szewczyk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910366.5A external-priority patent/GB9910366D0/en
Priority claimed from GBGB0008179.4A external-priority patent/GB0008179D0/en
Priority to CA002370801A priority Critical patent/CA2370801A1/en
Priority to NZ515048A priority patent/NZ515048A/en
Priority to MXPA01011267A priority patent/MXPA01011267A/en
Priority to EP00929488A priority patent/EP1212305A2/en
Priority to JP2000617189A priority patent/JP2002544200A/en
Priority to IL14612400A priority patent/IL146124A0/en
Application filed by Glaxo Group Ltd, David Colclough, Anne Hodgson, Jerzy Ryszard Szewczyk filed Critical Glaxo Group Ltd
Priority to HU0201181A priority patent/HUP0201181A3/en
Priority to AU47548/00A priority patent/AU4754800A/en
Priority to BR0010338-1A priority patent/BR0010338A/en
Priority to KR1020017014075A priority patent/KR20020012567A/en
Publication of WO2000068209A2 publication Critical patent/WO2000068209A2/en
Publication of WO2000068209A3 publication Critical patent/WO2000068209A3/en
Priority to NO20015397A priority patent/NO20015397L/en
Priority to HK02107684.4A priority patent/HK1046138A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

An enantiomerically enriched compound of Formula (I) is disclosed, processes for its preparation, pharmaceutical compositions containing it and the use therefore, for the treatment of CCK-A mediated diseases or conditions, such as obesity.
PCT/EP2000/003982 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives as cck-a receptor agonists WO2000068209A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
BR0010338-1A BR0010338A (en) 1999-05-06 2000-05-04 Enanciomerically enriched compound, pharmaceutical composition, method for treating a disease or condition mediated by cck-a, use of a compound, and process for the preparation of a compound
KR1020017014075A KR20020012567A (en) 1999-05-06 2000-05-04 1,5-Benzodiazepine Derivatives
HU0201181A HUP0201181A3 (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives, process for producing it and pharmaceutical composition containing it
MXPA01011267A MXPA01011267A (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives.
EP00929488A EP1212305A2 (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives as cck-a receptor agonists
JP2000617189A JP2002544200A (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivative
IL14612400A IL146124A0 (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives
CA002370801A CA2370801A1 (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives as cck-a receptor agonists
NZ515048A NZ515048A (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives
AU47548/00A AU4754800A (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives as CCK-A receptor agonists
NO20015397A NO20015397L (en) 1999-05-06 2001-11-05 1,5-Benzodiazepine derivatives
HK02107684.4A HK1046138A1 (en) 1999-05-06 2002-10-23 1,5-benzodiazepine derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9910366.5A GB9910366D0 (en) 1999-05-06 1999-05-06 1,5-Benzodiazepine Derivatives
GB9910366.5 1999-05-06
GB0008179.4 2000-04-05
GBGB0008179.4A GB0008179D0 (en) 2000-04-05 2000-04-05 Chemical process

Publications (2)

Publication Number Publication Date
WO2000068209A2 WO2000068209A2 (en) 2000-11-16
WO2000068209A3 true WO2000068209A3 (en) 2001-03-01

Family

ID=26244033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003982 WO2000068209A2 (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives as cck-a receptor agonists

Country Status (21)

Country Link
EP (1) EP1212305A2 (en)
JP (1) JP2002544200A (en)
KR (1) KR20020012567A (en)
CN (1) CN1161345C (en)
AR (1) AR022044A1 (en)
AU (1) AU4754800A (en)
BR (1) BR0010338A (en)
CA (1) CA2370801A1 (en)
CO (1) CO5170461A1 (en)
CZ (1) CZ20013988A3 (en)
HK (1) HK1046138A1 (en)
HU (1) HUP0201181A3 (en)
IL (1) IL146124A0 (en)
MX (1) MXPA01011267A (en)
MY (1) MY138319A (en)
NO (1) NO20015397L (en)
NZ (1) NZ515048A (en)
PE (1) PE20010110A1 (en)
PL (1) PL351546A1 (en)
TR (1) TR200103169T2 (en)
WO (1) WO2000068209A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035793A2 (en) * 2003-10-09 2005-04-21 Decode Genetics Ehf. Cckar markers and haplotypes associated with extreme weight conditions
EA010888B1 (en) 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Tetraazabenzo[e]azulene derivatives and analogs thereof
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646140A (en) * 1993-04-15 1997-07-08 Glaxo Wellcome Inc. 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646140A (en) * 1993-04-15 1997-07-08 Glaxo Wellcome Inc. 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRISTOL, J. A.: "Annual reports in medicinal chemistry", 1990, ACADEMIC PRESS, INC., SAN DIEGO,, XP002150744 *
GAVIN C. HIRST ET AL.: "Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): optimization of the C3 amino substituent", JOURNAL OF MEDICINAL CHEMISTRY., vol. 39, no. 26, - 1996, AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 5236 - 5245, XP002150743, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
CA2370801A1 (en) 2000-11-16
HK1046138A1 (en) 2002-12-27
HUP0201181A2 (en) 2002-12-28
CN1362949A (en) 2002-08-07
PL351546A1 (en) 2003-05-05
AR022044A1 (en) 2002-09-04
BR0010338A (en) 2002-02-13
WO2000068209A2 (en) 2000-11-16
NO20015397D0 (en) 2001-11-05
IL146124A0 (en) 2002-07-25
PE20010110A1 (en) 2001-03-05
NZ515048A (en) 2004-01-30
NO20015397L (en) 2001-11-05
MY138319A (en) 2009-05-29
EP1212305A2 (en) 2002-06-12
JP2002544200A (en) 2002-12-24
AU4754800A (en) 2000-11-21
MXPA01011267A (en) 2002-05-06
CZ20013988A3 (en) 2002-02-13
TR200103169T2 (en) 2002-04-22
KR20020012567A (en) 2002-02-16
CO5170461A1 (en) 2002-06-27
CN1161345C (en) 2004-08-11
HUP0201181A3 (en) 2003-10-28

Similar Documents

Publication Publication Date Title
AP2000001860A0 (en) Hypolipidemic benzothiazepine compounds.
CA2343236A1 (en) 4,4-biarylpiperidine derivatives
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
TWI256389B (en) Novel hPPAR delta agonists and pharmaceutical compositions comprising the same
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
PL367682A1 (en) Dolastatin 10 derivatives
IL161829A (en) 1,2,4 - thiadiazole derivatives, some of which are novel and pharmaceutical compositions comprising the same for treating disorders mediated by melanocortin receptor modulators
HUP9701694A3 (en) Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MY128659A (en) Novel aminodicarboxylic acid derivatives having pharmaceutical properties
HK1031869A1 (en) 1-Ä(1-Substituted-4-piperidinyl)methylÜ-4-piperdine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds.
HK1048990A1 (en) Novel compounds.
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
ZA200110540B (en) Novel diphenyl-piperidine derivate.
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
HK1068332A1 (en) Pyrane derivatives as both ace-and nep-inhibitors
IL157065A0 (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
CA2442210A1 (en) Aryl oxime-piperazines useful as ccr5 antagonists
WO2000068209A3 (en) 1,5-benzodiazepine derivatives as cck-a receptor agonists
NZ320522A (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds
CA2299036A1 (en) 4-phenyl-4-heteroarylpiperidine derivatives
HK1046284A1 (en) Polymorphs of crystalline azabicyclo(2,2,2)octan-3-aminecitrate and their pharmaceutical compositions.
CA2309439A1 (en) 3-(3-hydroxyphenyl)-3-amino-propionamide derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/1118/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2000929488

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/08827

Country of ref document: ZA

Ref document number: 515048

Country of ref document: NZ

Ref document number: 200108827

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 47548/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2370801

Country of ref document: CA

Ref document number: 2370801

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/03169

Country of ref document: TR

Ref document number: 1020017014075

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 617189

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011267

Country of ref document: MX

Ref document number: PV2001-3988

Country of ref document: CZ

Ref document number: 09980987

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 008099324

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: PV2001-3988

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020017014075

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000929488

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017014075

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000929488

Country of ref document: EP